(Q34530205)

2 August 2017

1 reference

title

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus (English)

1 reference

2 August 2017

0 references

Mariele Briones

1 reference

2 August 2017

Mandeep Bajaj

series ordinal

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

published in

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

2 August 2017

page(s)

1055-1064

1 reference

Postprandial blood glucose. American Diabetes Association

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Racial and ethnic differences in glycemic control of adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Exon duplication and divergence in the human preproglucagon gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Minireview: the glucagon-like peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Clinical review 102: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.1055

10.1517/14656566.7.8.1055

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference